VABYSMO 120mg/ml solution for injection EGIS ORIGINAL MEDICINE
Chemical substance: faricimab
ATC code: S01LA09 • Sensory organs | Ocular vascular disorder agents | Antineovascularisation agents
Active substance
Results for the substance faricimab
1 result
About this active substance
Faricimab is a medication used to treat retinal conditions such as age-related macular degeneration and diabetic macular edema. It works by inhibiting factors that promote the formation of abnormal blood vessels in the retina, helping to maintain vision and prevent its deterioration.
Faricimab is administered through intraocular injections performed by an ophthalmologist under sterile conditions. The frequency of administration is determined by the progression of the disease and the patient's response to treatment. It is important for the patient to keep appointments for injections and follow the doctor's recommendations.
Side effects may include eye discomfort, redness, foreign body sensation, or, rarely, serious eye infections. Any change in vision or unusual symptoms should be reported immediately to the ophthalmologist for prompt evaluation and treatment.
Faricimab is a modern and effective option for maintaining vision in patients with retinal conditions. Careful monitoring and collaboration with the medical team are essential for treatment success and prevention of complications.
Faricimab is administered through intraocular injections performed by an ophthalmologist under sterile conditions. The frequency of administration is determined by the progression of the disease and the patient's response to treatment. It is important for the patient to keep appointments for injections and follow the doctor's recommendations.
Side effects may include eye discomfort, redness, foreign body sensation, or, rarely, serious eye infections. Any change in vision or unusual symptoms should be reported immediately to the ophthalmologist for prompt evaluation and treatment.
Faricimab is a modern and effective option for maintaining vision in patients with retinal conditions. Careful monitoring and collaboration with the medical team are essential for treatment success and prevention of complications.